2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
06/06/17NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers. First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed Immunotherapy Trials Across All Tumor Types CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 6, 2017-- NantKwest and Nantworks today announced at the 2017 ... 
Printer Friendly Version
06/02/17NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017
CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 2, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7th, in New York City at 8:30 a.m. ET. In conjunction with this conference, Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, will be participating in a panel discussion ... 
Printer Friendly Version
05/18/17NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team CULVER CITY, Calif.--(BUSINESS WIRE)--May 18, 2017-- NantKwest Inc. (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced today the appointment of John Lee, MD, FACS, as Sen... 
Printer Friendly Version
05/16/17NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Company adds esteemed pediatric, adolescent and young adult oncology expert to leadership team CULVER CITY, Calif.--(BUSINESS WIRE)--May 16, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced today the appointment of Leona... 
Printer Friendly Version
05/15/17NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--May 15, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that members of the company's management team will be presenting at the 2017 Bank of America Healthcare Conference on Thursday, May 18th in Las Vegas, Nevada at 11:20AM PT. About NantKwest Inc. NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage ... 
Printer Friendly Version
05/09/17NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
The NANT Cancer Vaccine, the First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as the Complementary Diagnostic for All Tumor Types A Cancer Breakthroughs 2020 Milestone to Address Multiple Cancer Types at All Stages of Disease CULVER CITY, Calif.--(BUSINESS WIRE)--May 9, ... 
Printer Friendly Version
04/04/17NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA   April 4, 2017 -  NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Joining NantKwest as a new investor in Viracta is Wicklow Capital. Viracta's founding investors, Latterell Venture... 
Printer Friendly Version
03/20/17NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced today that the FDA has granted Orphan Drug Designation to the company’s activated natural killer (aNK) cell therapy for treatment of patients... 
Printer Friendly Version
03/06/17NantKwest to Present at Upcoming Investor Conferences
CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference on Wednesday, March 8th, at 9:20am ET in Boston, MA 29th Annual Roth Conference on Monday, March 13th, at 12:00pm ET in Dana Point, CA ... 
Printer Friendly Version
01/23/17Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized the company's Investigational New Drug Application (IND) for its ... 
Printer Friendly Version